Malaysia Pharmaceuticals and Healthcare Report Q2 2016

101 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: We hold a bullish outlook for Malaysia’s pharmaceutical market over our forecast period. We
believe the government’s commitment to expanding healthcare access coupled with the country’s growing
population and disease burden will drive medicine demand in the coming years. Furthermore, the signing of
the Trans-Pacific Partnership (TPP) agreement – after years of negotiation and uncertainty – will work to
strengthen multinational interest in the market, particularly patented drug manufacturers.
Headline Expenditure Projections
? Pharmaceuticals: MYR7.88bn (USD2.02bn) in 2015 to MYR8.59bn (USD2.05bn) in 2016; +9.0% in
local currency and +1.4% in US dollar terms. Forecast unchanged from last quarter.
? Healthcare: MYR45.85bn (USD11.73bn) in 2015 to MYR49.38bn (USD11.77bn) in 2016; +7.7% in
local currency and +0.2% in US dollar terms. Forecast unchanged from last quarter.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Malaysia 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Malaysia 2012-2020) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Malaysia 2012-2020) 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Malaysia 2012-2020) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Malaysia 2012-2020) 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Malaysia 2012-2020) 21
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Malaysia 2012-2020) 23
Generic Drug Market Forecast 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Malaysia 2012-2020) 26
OTC Medicine Market Forecast 27
Pharmaceutical Trade Forecast 30
Table: Pharmaceutical Trade Data And Forecasts (Malaysia 2014-2020) 32
Table: Pharmaceutical Trade Data And Forecasts local currency (Malaysia 2014-2020) 32
Industry Risk/Reward Index 33
Asia Pacific Risk/Reward Index 33
Malaysia Risk/Reward Index 39
Rewards 39
Risks 39
Market Overview 41
Epidemiology 41
Healthcare Sector 43
Table: 2011 Entry Point Projects Summary 45
Table: Healthcare Resources (Malaysia 2010-2015) 46
Table: Healthcare Personnel (Malaysia 2010-2015) 46
Table: Healthcare Activity (Malaysia 2010-2015) 47
Healthcare Insurance 47
Table: Main Features Of 1Care 47
Healthcare Funding 49
Healthcare Sector Developments 50
Table: Public Sector And Private Sector Healthcare Developments 50
Medical Tourism 51
Research & Development 52
Clinical Trials 54
Regulatory Review 55
Regulatory Regime 55
Table: Drug Applications by Type, 2002-2010 57
Table: Registered Pharmaceutical Products by Type, 2002-2010 57
Regulatory Developments 57
Intellectual Property Issues 62
Pricing Regime 66
Competitive Landscape 68
Domestic Industry 68
Foreign Industry 71
Table: Table: Multinational Market Activity 72
Table: Leading Malaysian Pharmaceutical And Healthcare Companies 73
Culture-Specific Medicines 73
Pharmaceutical Distribution 75
Table: Drug Wholesalers & Importers, 2002-2010 76
Pharmaceutical Retail Sector 76
Company Profile 79
Chemical Company Of Malaysia 79
Kotra Pharma 82
Novartis 84
Ranbaxy Malaysia 86
Sanofi 88
Demographic Forecast 90
Table: Population Headline Indicators (Malaysia 1990-2025) 91
Table: Key Population Ratios (Malaysia 1990-2025) 91
Table: Urban/Rural Population & Life Expectancy (Malaysia 1990-2025) 92
Table: Population By Age Group (Malaysia 1990-2025) 92
Table: Population By Age Group % (Malaysia 1990-2025) 93
Glossary 95
Methodology 97
Pharmaceutical Expenditure Forecast Model 97
Healthcare Expenditure Forecast Model 97
Notes On Methodology 98
Risk/Reward Index Methodology 99
Index Overview 100
Table: Pharmaceutical Risk/Reward Index Indicators 100
Indicator Weightings 101

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Malaysia 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Malaysia 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Malaysia 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Malaysia 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Malaysia 2012-2020)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Malaysia 2012-2020)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Malaysia 2012-2020)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Malaysia 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (Malaysia 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Malaysia 2014-2020)
Table: 2011 Entry Point Projects Summary
Table: Healthcare Resources (Malaysia 2010-2015)
Table: Healthcare Personnel (Malaysia 2010-2015)
Table: Healthcare Activity (Malaysia 2010-2015)
Table: Main Features Of 1Care
Table: Public Sector And Private Sector Healthcare Developments
Table: Drug Applications by Type, 2002-2010
Table: Registered Pharmaceutical Products by Type, 2002-2010
Table: Table: Multinational Market Activity
Table: Leading Malaysian Pharmaceutical And Healthcare Companies
Table: Drug Wholesalers & Importers, 2002-2010
Table: Population Headline Indicators (Malaysia 1990-2025)
Table: Key Population Ratios (Malaysia 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Malaysia 1990-2025)
Table: Population By Age Group (Malaysia 1990-2025)
Table: Population By Age Group % (Malaysia 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • India Pharmaceuticals and Healthcare Report Q2 2016BMI View: The shift in the pharmaceutical landscape due to the Trans-Pacific Partnership (TPP) will be negative for the Indian generic drug industry. Collectively accounting for 40% of medicine exports from India, the 12 member markets of the TPP will see stronger patent protection and longer regulatory data protection. This coupled with the introduction of a patent linkage system will serve to deter the introduction of Indian generic drugs and curtail their overall growth. Headline […]
  • Kuwait Pharmaceuticals and Healthcare Report Q3 2015BMI View: While the losses incurred by Yiaco, the largest drug distributor in Kuwait, highlight a deteriorated near-term operating environment, with markedly lower prices as a result of the ongoing Gulf Cooperation Council (GCC) medicine price unification process, drugmakers will continue to perceive high long-run returns. Exhibiting a high and very costly burden of diabetes and cardiovascular conditions, Kuwait's aging population will continue to receive rising access to quality […]
  • Malaysia Pharmaceuticals and Healthcare Report 2016BMI View: Although the 2016 health budget assigned to the ministry of health comes in lower than in 2015, we believe the government remains committed to expanding healthcare access. The construction of more health clinics under the 1Malaysia brand and the increased number of zero-rated drugs under the Goods and Service Tax will help make medicines and services more affordable for low-income patients. However, the fall of the ringgit may have a negative impact drug costs in the coming […]
  • Mexico Pharmaceuticals and Healthcare Report Q1 2015BMI View: The rising consumption of generic medicines will reshape Mexico's pharmaceutical industry. We expect the prevalence of generic drugs to increase rapidly over the forecast period - driven by government regulations supporting the sector and rising public awareness of off-patented medicines. Headline Expenditure Projections ? Pharmaceuticals: MXN172.74bn (USD13.53bn) in 2013 to MXN184.46bn (USD14.19bn) in 2014; +6.8% in local currency terms and +4.9% in US dollar terms. […]
  • Norway Pharmaceuticals and Healthcare Report Q4 2014BMI View: While the Norwegian government's pro-generic stance will continue to support growth in the country's off-patent medicines market, we highlight that the loss of market value in the patented drugs sector will not translate into an equivalent gain for the generic drugs market as a result of the much lower cost of generics. Headline Expenditure Projections Pharmaceuticals: NOK19.90bn (USD3.36bn) in 2013 to NOK20.28bn (USD3.29bn) in 2014; 1.93% in local currency […]